SEC Company Response from Enlivex Ltd. (ENLV) (CIK 0001596812) (ENLV) — Aug 10, 2015
Enlivex Ltd. (ENLV) (CIK 0001596812)
Date: Aug. 10, 2015 · CIK: 0001596812 · Accession: 0001144204-15-047813
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206032
Letter
RE: Bio Blast Pharma Ltd.
August 10, 2015
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, DC 20549
Attn: Jeffrey P. Riedler, Division of Corporate Finance
Registration Statement on Form F-3
Filed on August 3, 2015
File No. 333-206032
Ladies and Gentlemen:
Bio Blast Pharma Ltd. (“BioBlast”) hereby requests acceleration of the effectiveness of the above-referenced registration statement pursuant to Rule 460 and Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on August 12, 2015, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.
BioBlast acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the above-referenced registration statement effective, it does not foreclose the Commission from taking any action with respect to the above-referenced registration statement;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the above-referenced registration statement effective, does not relieve BioBlast from its full responsibility for the adequacy and accuracy of the disclosure in the above-referenced registration statement; and
· BioBlast may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Securities and Exchange Commission
August 10, 2015
Page 2
BioBlast understands that the Commission will consider this request for acceleration of the effective date of this above-referenced registration statement as a confirmation of the fact that BioBlast is aware of its respective responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the referenced above registration statement.
Very truly yours,
/s/ Colin Foster
Show Raw Text
CORRESP
1
filename1.htm
August 10, 2015
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, DC 20549
Attn: Jeffrey P. Riedler, Division of Corporate Finance
RE:
Bio Blast Pharma Ltd.
Registration Statement on Form F-3
Filed on August 3, 2015
File No. 333-206032
Ladies and Gentlemen:
Bio Blast Pharma Ltd. (“BioBlast”)
hereby requests acceleration of the effectiveness of the above-referenced registration statement pursuant to Rule 460 and Rule
461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on
August 12, 2015, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.
BioBlast acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the above-referenced registration statement
effective, it does not foreclose the Commission from taking any action with respect to the above-referenced registration statement;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the above-referenced registration
statement effective, does not relieve BioBlast from its full responsibility for the adequacy and accuracy of the disclosure in
the above-referenced registration statement; and
· BioBlast may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.
Securities and Exchange Commission
August 10, 2015
Page 2
BioBlast understands that the Commission
will consider this request for acceleration of the effective date of this above-referenced registration statement as a confirmation
of the fact that BioBlast is aware of its respective responsibilities under the Securities Act and the Securities Exchange Act
of 1934, as amended, as they relate to the proposed public offering of the securities specified in the referenced above registration
statement.
Very truly yours,
/s/ Colin Foster
Colin Foster
Chief Executive Officer and President
Cc: Shy S. Baranov, Esq.